Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men
PHASE1CompletedINTERVENTIONAL
Enrollment
82
Participants
Timeline
Start Date
December 8, 2016
Primary Completion Date
April 30, 2019
Study Completion Date
April 30, 2019
Conditions
Healthy Volunteers
Interventions
DRUG
REGN1033
REGN1033
DRUG
REGN2477
REGN2477
OTHER
Placebo
Placebo
Trial Locations (2)
Unknown
Auckland
Christchurch
All Listed Sponsors
lead
Regeneron Pharmaceuticals
INDUSTRY
NCT02943239 - Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men | Biotech Hunter | Biotech Hunter